Please login to the form below

Not currently logged in
Email:
Password:

PTC Therapeutics

This page shows the latest PTC Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Europe responding to gene therapy challenge, but picture remains fragmented

Europe responding to gene therapy challenge, but picture remains fragmented

deal. Extra notes of caution about the difficult of gaining access for such therapies came from Axel Boehnke director market access, PTC Therapeutics, who stressed that the CAR-T deals could ... Finally, Sarah Pitluck, head of global pricing and

Latest news

  • Havas Lynx Group scoops nine Golds at PM Society Awards Havas Lynx Group scoops nine Golds at PM Society Awards

    Other Gold winners included Aspen, Boeringher Ingelheim, Galderma, Johnson &Johnson, Mundipharma, Napp, Novartis, PTC Therapeutics, Shire, Teva, Tillotts Pharma and ViiV. ... Craft Award for Patient Support: Cognite for PTC Therapeutics. Target Award for

  • Duchenne UK backs Evox dystrophin delivery project Duchenne UK backs Evox dystrophin delivery project

    Funding will drive preclinical studies on dystrophin-bearing exosomes. Oxford University spin-out Evox Therapeutics has won a £656, 000 ($858, 000) grant from a UK medical charity to test its ... At the moment that includes already-market drugs that

  • Spinraza lifts Biogen ahead of Alzheimer’s data Spinraza lifts Biogen ahead of Alzheimer’s data

    time, as rival therapies such as oral liquid drug risdiplam (RG7916) developed by Roche and PTC Therapeutics and a one-off gene therapy from Novartis/Avexis that was filed for approval

  • Roche drug hits the mark in spinal muscular atrophy studies Roche drug hits the mark in spinal muscular atrophy studies

    Risdiplam – which Roche licenses from PTC Therapeutics – is a small molecule that targets and encourages the SMN2 gene to produce a greater amount of functional SMN protein, which is lacking in

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics ... Pfizer still has an iron in the DMD fire, in the form of its Bamboo

More from news
Approximately 8 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Pharma deals during November 2014 Pharma deals during November 2014

    Prosensa has just begun a rolling submission of the application. BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in ... This month also saw CAR-T “wunder-kid” Juno Therapeutics

  • Pharma deals during January 2014 Pharma deals during January 2014

    Firstly, there was the acquisition of Merck's subsidiary, Sirna Therapeutics for $175m upfront in cash and equity. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

  • Orchard Therapeutics appoints Mark Rothera as CEO Orchard Therapeutics appoints Mark Rothera as CEO

    He joins from PTC Therapeutics. London, UK-based Orchard Therapeutics has appointed Mark Rothera as its new president and chief executive officer at a time when the group progresses its clinical ... Prior to his new role, Rothera served as chief

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success
This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change
...

Infographics